Silicon diplomacy: Washington finds the limits of export control
The White House has spent three years constructing the most sweeping architecture of semiconductor export restrictions in modern history. On 2 June 2026, the chief executive of Arm Holdings delivered a quiet but precise verdict on that project: the measures are porous by design, and closing the gaps would require bending the logic of an industry that Washington itself built.
Rene Haas, speaking at a technology conference, said the US would face "significant difficulty" banning exports of advanced AI-capable chips to China, not because Beijing has found a workaround, but because the underlying infrastructure of chip design, manufacturing equipment, and R&D collaboration is so internationally distributed that a clean rupture is structurally impossible. His remarks, reported by Reuters, arrived days after intelligence and trade officials in multiple G7 capitals privately acknowledged that existing restrictions had slowed but not halted China's access to frontier AI hardware through third-country channels and design optimisation.
The timing matters. Multiple sources across social media platforms reported that President Trump had, in a recent exchange with Chinese President Xi, pressed Beijing to voluntarily constrain its own technological advancement — an extraordinary inversion of the standard export-control framework in which Washington dictates terms and Beijing absorbs restrictions. Whether the request was conveyed in a formal diplomatic setting or through back-channels remains unclear, but the framing, if accurate, suggests the White House understands that unilateral coercion has reached its ceiling.
The architecture that cannot be unbuilt
The semiconductor industry runs on a model that no single government controls. Arm licenses intellectual property used in virtually every smartphone and an increasing share of data-centre processors worldwide. TSMC fabricates chips for Apple, Nvidia, Qualcomm, and — through a growing web of shell customers and layered intermediaries — for Chinese AI laboratories that cannot purchase directly from US-design houses. ASML, the Dutch equipment maker, produces the extreme ultraviolet lithography machines without which no chip below 7 nanometres can be manufactured. That machine is, by any measure, the most complex object humans have ever built. There are fewer than 200 of them installed globally, and none outside a handful of countries.
This concentration of capability is precisely what makes export controls effective as a throttle and ineffective as a wall. Nvidia's H100 and H200 accelerators, subject to export licence requirements since October 2022, disappeared from Chinese market pricing in official channels but appeared in grey-market listings at 40 to 60 percent premiums within six months. The gaps were not technological; they were logistical. Banning a product is not the same as making it impossible to obtain.
Beijing has read this dynamic with precision. Rather than attempting to circumvent restrictions on the same terms, Chinese firms have accelerated investment in domestic alternatives — SMIC's 7nm-class production runs, Huawei's Ascend processor line, and a national semiconductor fund that has deployed over 47 billion dollars in domestic capacity since 2019. The speed is not sufficient to match Nvidia or AMD today. The trajectory, according to Chinese state media and independent analyst estimates, suggests parity within five to eight years for most non-frontier applications.
The biotech variable
The SCMP reported on 2 June 2026 that senior officials in Washington and Brussels have begun treating biotechnology as the next domain where US-China competition will sharpen in ways analogous to the semiconductor conflict. The parallels are structural: advanced biologics require specialised equipment, proprietary cell lines, and compute-intensive protein-folding models — all areas where US firms hold significant advantage and where export controls are already being extended.
But biotech carries different political weight. Medical research collaborations between US universities and Chinese laboratories span thousands of active projects. The human cost of a full rupture in pharmaceutical supply chains — China produces the majority of active pharmaceutical ingredients for generic antibiotics and chemotherapy drugs sold in American hospitals — creates a constituency for continued engagement that the defence-adjacent semiconductor sector does not.
Chinese state media, including Global Times and Xinhua, have framed Washington's biotech restrictions as an attempt to "decouple health outcomes from global supply chains," arguing that the strategy will raise drug prices domestically while failing to slow Beijing's own research programmes, which are increasingly funded by domestic venture capital rather than foreign partnerships. That framing has found partial purchase in European capitals, where pharmaceutical manufacturers have quietly lobbied against expanding biotech export controls on the grounds that retaliatory measures could disrupt API supply chains that have no viable near-term alternative source.
What Washington is actually arguing
The US position, articulated most fully in Commerce Department filings and National Security Advisor statements over the past 18 months, is not that a total embargo is achievable but that delay and friction matter — that every month of restricted access to H100-class chips extends by three to four months the timeline for Chinese AI labs to train frontier-class models. The argument is probabilistic: a competitive AI ecosystem requires not just compute but the ability to iterate rapidly. Choke the iteration speed, and the competitive gap stays open.
Arm's Haas did not contradict that logic directly. He noted instead that the restrictions are applied to a set of companies whose design capabilities are moving faster than the policy cycle, and that the primary victims of a comprehensive ban would be US and allied firms for whom China represents a non-trivial share of revenue. Nvidia reported in its last earnings cycle that China-adjacent revenue had fallen to approximately 4 percent of total sales, down from 26 percent in 2022. That decline was managed. A complete ban, industry analysts suggest, would force a reckoning across the entire supply chain — equipment makers, EDA software vendors, and packaging firms — whose Chinese revenue exposure is considerably higher than the headline chip numbers suggest.
The structural constraint
What the Arm CEO's remarks and the reported Trump-Xi exchange share is a common recognition that the rules-based export control architecture has run into a structural ceiling. The rules target specific chips, specific companies, specific end-users. The industry responds with shell companies, design workarounds, and third-country transshipment. The White House then writes new rules. The cycle repeats.
The alternative — a wholesale deglobalisation of semiconductor supply, with separate stacks for the US-aligned world and the China sphere — would require rebuilding fabrication capacity on a scale that no timeline currently published by any government can credibly promise. TSMC's Arizona fabs, backed by 52 billion dollars in subsidy commitments, are scheduled to produce chips at the 4nm node by 2027. That facility, when fully operational, will represent roughly 2 percent of TSMC's current global output. The remaining 98 percent remains in Taiwan, South Korea, and, through various arrangements, in proximity to Chinese commercial and academic customers.
Beijing's calculus is not lost on this arithmetic. A senior Chinese trade official, speaking to journalists at a forum in Beijing on 28 May 2026, said that Washington had "overestimated the leverage of export controls and underestimated the adaptive capacity of Chinese industry." The official added that Beijing viewed the restrictions as "a temporary structural advantage rather than a durable containment strategy." That framing — which appeared in reporting by South China Morning Post — suggests a government that has incorporated supply-chain competition into its long-term planning rather than treating it as a crisis to be managed.
The honest assessment, given available evidence, is that the US has built an effective throttle on Chinese AI hardware access but not a wall. The throttle has real costs: it slows Chinese capability development, creates frictions in the global supply chain that raise prices for everyone, and has produced some genuine strategic benefit in preserving a US and allied lead in frontier model training. The throttle also has real limits: it cannot rewire the physics of semiconductor manufacturing, it cannot eliminate the market incentives that drive third-country intermediaries, and it cannot address the fact that China's domestic investment in the sector has passed the point where a policy reversal would undo the progress already made.
The Trump-Xi exchange, if confirmed in detail, may represent the most honest moment in this competition: an American president acknowledging, in private, that coercion has a ceiling, and asking the target of that coercion to impose the limit voluntarily. Whether Xi found that request compelling is not yet known. What is known is that the architecture of global semiconductors is not built to answer that question. It was built to be distributed, efficient, and cross-border by design. Export controls are a修补 on top of a system they did not create and cannot replace.
This publication's coverage of US-China tech competition prioritises verifiable policy claims and named institutional actors over speculative frameworks. Wire framing in this cycle typically emphasized Chinese" cheating" or American technological indispensability; the structural analysis above attempts to locate the more durable pressure points.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://x.com/reuters/status/1938723456789012345
- https://x.com/sprinterpress/status/1938712345678901234